PHARMANIAGA BHD

KLSE (MYR): PHARMA (7081)

You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!

Last Price

0.435

Today's Change

-0.005 (1.14%)

Day's Change

0.435 - 0.44

Trading Volume

724,700

Financial

T4Q

31-Mar-2021

2020

31-Mar-2021

2019

31-Mar-2021

2018

31-Mar-2021

2017

31-Mar-2021

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Revenue

238

1000

110

900

600

Discussions
6 people like this. Showing 50 of 14,036 comments

notrealBoo

news or no news.. have to wait PP finish first.. and PP price is only 0.35

2 months ago

BobAxelrod

2nd PP to raise pocket change of 50 mill for working Capital???.........out of cash in Hand???

So, how to settle the 1 Billion Debts looming large??????? Mind you, it's 1 Billion, not 10 mill or 50 mill........!!

2 months ago

BobAxelrod

PP again for 50 mill....piggy bank smashed, Milo tin already kosong....RED Flags...........

Price should be at 12c........and below 10c upon legal actions from Banks.

2 months ago

Cipta

look this: https://www.businesstoday.com.my/2023/07/06/affin-banks-credit-costs-and-nim-issues-to-persists-midf/

Affin will have higher bad debt next quarter concurrent with expire of vaccine. Since under same group, boleh bincang la...😁

2 months ago

Runnerup

look good invite Warren buffett join for next PP....

2 months ago

Cipta

first PP at 35cent , how much u guess will be 2nd?

2 months ago

MohamedAqil

Harga PP ikut VWAP ?

2 months ago

mrupai

more pp price up more. pls 3 more pp

2 months ago

Runnerup

possible be want take bigger share percentage of this company...

2 months ago

tai yee

wow... PBB give high target price😏

2 months ago

Runnerup

wow booster vaccine Viagra come again ... high target price will achieve soon ...

2 months ago

Cryptolover

those who jump in because public bank cover get ready to lose money lol

2 months ago

Felix888

BobAssshole bodoh the Pharma share price already almost up 100% from bottom.

This kind of bodoh bookworm how to make money in share market? Adui!

2 months ago

pang72

This company is in risk of bankruptcy

2 months ago

Cipta

SC is doing the right job to ban 2nd PP. This GLC is making the bad example to ruin Bursa regulation. If 2nd, 3rd PP and plus can be done in the same year, what is the meaning of requiring Shareholders approval for 10% issuing limit?

2 months ago

Runnerup

QR report macam go back to 3 ..... ????

1 month ago

MohamedAqil

Bulan ni keluar QR. Tunjuk keuntungan atau kerugian?

1 month ago

stainlyho37

watch out..possible to break 0.45 again in short term...!!?

1 month ago

Sargon15

Hoping for mid term, getting out from PN17 huhu

1 month ago

Cookieyirl

Buy now 395 and keep half year wait for harvest

1 month ago

Newplayer01

Just buy. This company is good.

1 month ago

notrealBoo

wait for better price. enter below 0.40

4 weeks ago

notrealBoo

told you guys.. fake push to trap people.. regularisation not yet even submitted.

4 weeks ago

EngineeringProfit

G.g.

4 weeks ago

notrealBoo

crazy pump

3 weeks ago

Newplayer01

For those who listen to me, today u already Huat 🤣🤣

3 weeks ago

EngineeringProfit

Your name is deceiving- how to trust? Why don't u upgrade it to Old/Experiencedplayer ?

3 weeks ago

notrealBoo

only worry later sharp drop again like in july.

3 weeks ago

EngineeringProfit

Exactly....................(for window dressing only during this season of red sea)

3 weeks ago

Newplayer01

If compare with other Sifu I’m still a potato ma. Let’s see it together. I also curious how high this stock can fly.

3 weeks ago

Runnerup

what's latest news not yet annoying

3 weeks ago

Runnerup

On the sector outlook, Kenanga noted global healthcare expenditures are projected to reach a total of US$10 trillion by 2026, increasing from US$8.4 trillion in 2022. — Bloomberg

PETALING JAYA: In the recently-concluded second quarter 2023 (2Q23) results, companies in the healthcare sector saw a slight sequential deterioration in earnings delivery against the expectations of Kenanga Research.

The research firm said out of the six companies under its coverage, three came within its forecasts, while three others disappointed.

“Generally, private hospitals under our coverage were hit by less patients seeking treatment during the festive month.

“Viewed as a blip, both IHH Healthcare Bhd and KPJ Healthcare Bhd expect patients to return in subsequent quarters.

“On the other hand, Pharmaniaga Bhd was hit by higher-than expected operating cost,” it stated in a report.

According to the research firm, the weaker-than-expected showing from IHH in the first half of 2023 (1H23) was due to its Singapore and Turkiye operations.

“The Turkiye operations were hit by festive holidays compounded by long weekend holidays as well as the presidential election.

“On the other hand, IHH’s Singapore operation was hit by staff shortage which is easing gradually.”

KPJ’s 1H23 results came in within expectation thanks to higher patient throughput and higher bed occupancy rate (BOR) of 66% (compared to 52% in 1H22) as demand for non-Covid related services rebounded including elective surgeries cases.

The group’s net profit doubled thanks to better overhead absorption on an improved turnover, as well as reduced losses from its new hospitals.

On the sector outlook, Kenanga noted global healthcare expenditures are projected to reach a total of US$10 trillion by 2026, increasing from US$8.4 trillion in 2022, representing a compound annual growth rate of 3.5% during the five-year period.

“In 2023, we expect IHH’s revenue per inpatient growth of 10%-15% (versus. 18% in 2022 due to low base effect in 2021), inpatient throughput growth of 10%-15% and BOR of 60%-73% (versus 56%-70%% in 2022) for its hospitals in Malaysia, Singapore, India and Turkiye.

“We believe the key growth for its inpatient throughput and BOR will be the return of elective surgeries and medical travel, the addition of new beds and the first full-year contribution from the Acibadem Atasehir hospital.”

Similarly, it expects KPJ’s patient throughput to grow 14% (versus 12% in FY22) with BOR of 70%, which will be driven by the recovery in demand for its services, particularly, non-Covid related ones including elective surgeries.

Kenanga Research liked both the stocks for their pricing power being major private healthcare players.

3 weeks ago

notrealBoo

bad news for pharma, still can goreng

3 weeks ago

Runnerup

Can goreng till RM 1.... huat lol everyone happy ...

3 weeks ago

notinside751

this is very weird. goreng all the way without any indication. will it cut chives later?

2 weeks ago

dangdang2020

anything also can goreng in bolehland

2 weeks ago

Runnerup

PP rejected, TMR goreng opposite direction... waves Goreng along the journey.

2 weeks ago

Depeche

Maybe goreng one more time for sharks to escape with fat profits first

2 weeks ago

Runnerup

Goreng continues till Level 3 ..... Reserver more bullet to enter again .

2 weeks ago

EngineeringProfit

G.g

2 weeks ago

Elaphe

Next quarter report will be another round of impairment...kau kau down by time..

1 week ago

CyrusQ

Pending Delisted

1 week ago

CyrusQ

Pending Delisted ?

1 week ago

KiasiPu

When the halal insulin release to market?

9 hours ago

Post a Comment